Are HIV positive patients resistant to statin therapy?

Lipids in Health and Disease

Volumn 6, Issue , 2007, Pages

  Johns, Kevin W ^a   Bennett, Matthew T ^a   Bondy, Gregory P ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; CHOLESTEROL; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; STATISTICAL SIGNIFICANCE; BLOOD; DYSLIPIDEMIA; MIDDLE AGED; MULTIDRUG RESISTANCE; RETROSPECTIVE STUDY; VIROLOGY;

CHOLESTEROL; DRUG RESISTANCE, MULTIPLE, VIRAL; DYSLIPIDEMIAS; FEMALE; FLUOROBENZENES; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRIMIDINES; RETROSPECTIVE STUDIES; SULFONAMIDES;

EID: 38049005910     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-6-27     Document Type: Article

References (24)

1. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. A Carr J Miller M Law DA Cooper, AIDS 2000 14 F25 32 10.1097/00002030-200002180-00001 10716495
2. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. D Periard A Telenti P Sudre JJ Cheseaux P Halfon MJ Reymond SM Marcovina MP Glauser P Nicod R Darioli V Mooser, Circulation 1999 100 700 5 10449690
3. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. T Saint-Marc M Partisani I Poizot-Martin F Bruno O Rouviere JM Lang JA Gastaut JL Touraine, AIDS 1999 13 1659 67 10.1097/00002030-199909100-00009 10509567
4. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? D Klein LB Hurley CP Quesenberry Jr S Sidney, J Acquir Immune Defic Syndr 2002 30 471 7 12154337
5. HIV infection, highly active antiretroviral therapy and the cardiovascular system. G Barbaro, Cardiovasc Res 2003 60 87 95 10.1016/S0008-6363(02)00828-3 14522410
6. Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. M Mary-Krause L Cotte A Simon M Partisani D Costagliola, AIDS 2003 17 2479 86 10.1097/00002030-200311210-00010 14600519
7. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. MP Dube JH Stein JA Aberg CJ Fichtenbaum JG Gerber KT Tashima WK Henry JS Currier D Sprecher MJ Glesby Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Disease Society of America, Clin Infect Dis 2003 37 613 27 10.1086/378131 12942391
8. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. SR Penzak SK Chuck GV Stajich, Pharmacotherapy 2000 20 1066 71 10.1592/phco.20.13.1066.35033 10999499
9. Rosuvastatin in the management of hyperlipidemia. JW Cheng, Clin Ther 2004 26 1368 87 10.1016/j.clinthera.2004.09.005 15531000
10. Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. L Calza V Colangeli R Manfredi G Legnani L Tampellini D Pocaterra F Chiodo, AIDS 2005 19 1103 5 15958843
11. A randomised, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. J Miller D Brown J Amin J Kent-Hughes M Law J Kaldor DA Cooper A Carr, AIDS 2002 16 2195 200 10.1097/00002030-200211080-00012 12409741
12. Influence of pravastatin on carotid artery structure and function in dyslipidemic HIV-infected patients receiving antiretroviral therapy. F Boccara T Simon K Lacombe A Cohen B Laloux E Bozec S Durant PM Girard S Laurent P Boutouyrie, AIDS 2006 20 2395 8 10.1097/QAD.0b013e32801120e3 17117030
13. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. S Stender H Schuster P Barter C Watkins D Kallend MERCURY I Study Group, Diabetes Obes Metab 2005 7 430 8 10.1111/j.1463-1326.2004.00450.x 15955130
14. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomised, double-blind, 52-week trial. WV Brown HE Bays DR Hassman J McKenney R Chitra H Hutchinson E Miller Rosuvastatin Study Group, Am Heart J 2002 144 1036 43 10.1067/mhj.2002.129312 12486428
15. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. M Hirsch JC O'Donnell P Jones, Eur J Cardiovasc Prev Rehabil 2005 12 18 28 10.1097/00149831-200502000-00004 15703502
16. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. AG Olsson H Istad O Luurila L Ose S Stender J Tuomilehto O Wiklund H Southworth J Pears JW Wilpshaar Rosuvastatin Investigators Group, Am Heart J 2002 144 1044 51 10.1067/mhj.2002.128049 12486429
17. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. AG Olsson J Pears J McKellar J Mizan A Raza, Am J Cardiol 2001 88 504 8 10.1016/S0002-9149(01)01727-1 11524058
18. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. JM McKenney PH Jones MA Adamczyk VA Cain BS Bryzinski JW Blasetto The STELLAR Study Group, Curr Med Res Opin 2003 19 689 98 10.1185/030079903125002405 14687438
19. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. M Davidson P Ma EA Stein AM Gotto Jr A Raza R Chitra H Hutchinson, Am J Cardiol 2002 89 268 75 10.1016/S0002-9149(01)02226-3 11809427
20. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. DW Schneck RH Knopp CM Ballantyne R McPherson RR Chitra SG Simonson, Am J Cardiol 2003 91 33 41 10.1016/S0002-9149(02)02994-6 12505568
21. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomised double blind crossover trial. D Hurlimann R Chenevard F Ruschitzka M Flepp F Enseleit M Bechir R Kobza J Muntwyler B Ledergerber TF Luscher G Noll R Weber, Heart 2006 92 110 2 10.1136/hrt.2004. 056523 15797933
22. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. JH Stein MA Merwood JL Bellehumeur SE Aeschlimann CE Korcarz GL Underbakke ME Mays JM Sosman, Am Heart J 2004 147 E18 15077088
23. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). Y Sawayama C Shimizu N Maeda M Tatsukawa N Kinukawa S Koyanagi S Kashiwagi J Hayashi, J Am Coll Cardiol 2002 39 610 6 10.1016/S0735-1097(01) 01783-1 11849859
24. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. MT Bennett KJ Johns GP Bondy, Lipids Health Dis 2007 6 15 17565701 10.1186/1476-511X-6-15